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Abstract 
 
Vitamin D deficiency is widely prevalent and often severe in children and adults with chronic 
kidney disease (CKD). Although native vitamin D (25-hydroxyvitamin D [25(OH)D]) is thought to 
have pleiotropic effects on many organ systems, its skeletal effects have been most widely 
studied. 25(OH)D deficiency is causally linked with rickets and fractures in healthy children and 
those with CKD, contributing to the CKD ± mineral and bone disorder (MBD) complex. 
 
There are few studies to provide evidence for vitamin D therapy or guidelines for its use in CKD. 
A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-
MBD and Dialysis WGs have developed recommendations for the evaluation, treatment, and 
prevention of vitamin D deficiency in children with CKD. We present clinical practice 
recommendations for the use of ergocalciferol [vitamin D2] and cholecalciferol [vitamin D3] in 
children with CKD stages 2 to 5 and on dialysis. A parallel document addresses treatment 
recommendations for active vitamin D analogue therapy. 
 
The WG have performed an extensive literature review to include meta-analyses and 
randomized controlled trials in healthy children as well as children and adults with CKD, and 
prospective observational studies in children with CKD. The GRADE system has been used to 
develop and grade the recommendations. In the absence of applicable study data, the opinion 
of experts from the ESPN CKD-MBD and Dialysis WGs is provided, but clearly GRADE-ed as 
such and must be carefully considered by the treating physician, and adapted to individual 
patient needs as appropriate. 
 
 
 
Introduction 
Vitamin D deficiency is widely prevalent and often severe in children and adults with chronic 
kidney disease (CKD), and contributes to abnormalities in calcium (Ca), phosphate (P) and 
parathyroid hormone (PTH) homeostasis. The mineral dysregulation in CKD directly affects 
bone strength, mineralisation1;2, and architecture1 and is called CKD ± mineral and bone 
disorder (CKD-MBD)3. CKD-MBD in childhood presents multiple obstacles to bone accrual2;4 
resulting in bone pain, deformities5;6, growth retardation7 and fractures2;4. 
 
Most tissues in the body have a vitamin D receptor and the enzymatic machinery to convert 
µQXWULWLRQDO¶ -hydroxyvitamin D [25(OH)D] to the active form 1,25-dihydroxyvitamin D 
[1,25(OH)2D] for local use. Converging data from in vitro, clinical and epidemiological studies 
suggests that in addition to the effects of vitamin D on calcium homeostasis and PTH 
regulation8, vitamin D may also play a role in the prevention of cardiovascular disease, anaemia, 
infectious and autoimmune conditions, renoprotection9;10, glycaemic control and prevention of 
some common cancers. Both nutritional vitamin D supplements and activated vitamin D 
analogues are routinely used in children with CKD. However, there are few studies to provide 
evidence for vitamin D associated outcomes in CKD. In the absence of evidence, guidelines 
from international committees like Kidney Disease Outcomes Quality Initiative (KDOQI)11;12 and 
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Kidney Disease Improving Global Outcomes (KDIGO)3 tend to be deliberately vague, leaving 
physicians, patients and health commissioners with few definitive treatment recommendations. 
 
We present clinical practice recommendations for the use of native vitamin D therapy 
(ergocalciferol [vitamin D2] and cholecalciferol [vitamin D3]) in children with CKD stages 2 to 5 
and on dialysis (stage 5D). This document covers recommendations for the assessment of 
vitamin D status, optimal levels of 25(OH)D and its monitoring, and recommendations for native 
vitamin D supplementation. A second document in parallel with this one covers treatment 
recommendations for active vitamin D analogue therapy (Ref xx). The recent Cochrane Review 
on interventions for metabolic bone disease in children with CKD13 and the evidence tables from 
the KDIGO CKD-MBD update document14 were used to evaluate all available studies, and in 
addition, the core working group (WG) have performed an extensive literature review to include 
additional systematic reviews, randomized controlled trials (RCTs) and prospective 
observational studies. The GRADE system has been used to develop and grade the 
recommendations. In the absence of applicable study data, the opinion of experts from the 
European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs is provided, 
but clearly GRADE-ed as such and must be carefully considered by the treating physician, and 
adapted to individual patient needs as appropriate. These clinical practice recommendations will 
be audited by the ESPN CKD-MBD and Dialysis WGs and revised periodically. Research 
recommendations to study key vitamin D outcome measures in children are suggested in the 
parallel document (Ref xx). 
  
 
 
 
Methods 
 
Overview of the guideline development group composition and task distribution   
Three groups were assembled to perform different functions: a core leadership group, an 
external advisory panel and a voting panel. The core group comprised Paediatric Nephrologists 
who are board members of the ESPN CKD-MBD and Dialysis WGs, a paediatric pharmacist 
and a biochemist. The chair and all members of the core panel had no relevant conflicts of 
interest. The core leadership group was responsible for defining the scope of the project, 
formulating the clinical questions to be addressed by the recommendations, performing a 
literature review, developing evidence tables, rating the quality of evidence, conducting the 
voting panel, and drafting the manuscript. The external advisory group included an expert in 
paediatric metabolic bone disease (NB), an adult nephrologist who is the chair of the CKD-MBD 
WG of the European Renal Association ± European Dialysis and Transplant Association (ERA-
EDTA; MC), and a guideline methodologist from European Renal Best Practice, the guideline 
development body of the ERA-EDTA (EN). The voting group was independent of the literature 
review group and comprised all members of the ESPN CKD-MBD and Dialysis groups. Voting 
group members were sent the draft guideline document and all evidence tables and were 
responsible for reviewing the evidence, GRADE-ing the recommendations and suggesting re-
wording of recommendations if appropriate. Comments received from all members of the voting 
group were collated into a single document and discussed at a meeting of the core working 
group with input from the external advisory group. A final document was then compiled and 
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circulated to the voting group for their opinion. We have not included children with CKD and 
their families in developing the recommendations. 
 
 
Developing the PICO questions 
Guidelines are most useful when they provide specific actionable advice on choosing between 
alternative approaches in particular clinical situations15. Therefore, as recommended by the 
GRADE method, we developed clinical question to be addressed by the recommendations 
under the following categories: the Patient (or Population) to whom the recommendation will 
DSSO\ WKH ,QWHUYHQWLRQ EHLQJ FRQVLGHUHG WKH &RPSDULVRQ ZKLFK PD\ EH ³QR DFWLRQ´ RU DQ
alternative intervention); and the Outcomes affected by the intervention (PICO)15. These PICO 
elements were arranged into the questions to be addressed in the literature searches. Each 
PICO question then formed the basis for a recommendation. 
 
Population covered  
We focus on children below 18 years of age with CKD stages 2-5D (estimated glomerular 
filtration rate below 90ml/min/1.73m2, and those on dialysis) for this clinical practice 
recommendation. The pathophysiological processes of CKD-MBD are not seen in CKD stage 1, 
hence we have not addressed this cohort in these recommendations. Children with kidney 
transplants are not included as other confounding issues such as immunosuppressive therapy 
may influence vitamin D status. 
 
Intervention and comparators 
Recommendations have been developed on native vitamin D therapy (cholecalciferol and 
ergocalciferol). These have been compared with no treatment, placebo or other native vitamin D 
analogues.   
 
Outcomes addressed 
We address recommendations for serum 25(OH)D based on its skeletal effects (including 
biochemical effects) only. The guideline committee acknowledges that there may be potential 
effects of vitamin D on multiple organ systems with possible beneficial effects such as the 
management of anaemia of CKD16;17, enhancing immune response18, reduction in proteinuria 
and attenuating CKD progression10;19. However, most of these data are based on pre-clinical 
studies or low-grade association studies in children. The guideline committee agreed that at our 
current state of knowledge, vitamin D supplementation exclusively for the prevention or 
management of non-osseous outcomes in children with CKD cannot be recommended. 
 
Importantly, although PTH is widely used as a surrogate end-point, it is a relatively poor marker 
of bone morphology in CKD1. There are no RCT data in CKD patients to show an effect of 
native vitamin D supplementation on growth or fracture risk. An association, that is likely causal, 
between PTH and skeletal outcomes has been shown in in vitro studies, animal experiments 
and observational studies; PTH-mediated increase in osteoclastic activity creates local foci of 
bone loss, and coupled with hypocalcaemia that leads to poor osteoid mineralisation, this 
results in a generalized decrease in bone mineral density (BMD), causing rickets and 
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osteopenia20;21. PTH is accepted as a valid surrogate through which the effects of vitamin D can 
be assessed. It is important that other modifiers of secondary hyperparathyroidism, including 
serum calcium, ionised calcium, phosphate, PTH, alkaline phosphatase, and 25(OH)D, are 
assessed together, with particular importance to trends in values, and appropriately managed 
through diet, use of calcium-based or calcium-free phosphate binder, ergo- or cholecalciferol 
supplementation, active vitamin D analogues and dialysis prescription. 
 
Literature search 
We initially set out to include all systematic reviews of RCTs and individual RCTs on native 
vitamin D therapy in children with CKD 2-5D. However, the core leadership group 
acknowledged there are few RCTs or prospective observational studies of native vitamin D 
treatment in children with CKD 2-5D. We have therefore elected to perform a wider review of the 
literature and include studies with primary skeletal endpoints (including biochemical endpoints) 
in the following cohorts: (i) All systematic reviews of RCTs in healthy children, children with 
nutritional rickets and adults; (ii)  All systematic reviews of RCTs, individual RCTs and 
prospective observational studies in children with CKD 2-5D; (iii)  All RCTs in adults with CKD 2-
5D; (iv)  All RCTs in healthy children or children with nutritional rickets. Medline was searched 
using the Pubmed interface through to 1st October 2016 using the search terms and strategy 
detailed in Supplemental table 1. Limits were pre-set to manuscripts published in the English 
language, and study design limits were applied as detailed in Supplemental table 1. Title and 
abstracts were reviewed by two independent reviewers (MW and RS). When there was 
disagreement regarding inclusion of the manuscript for this systematic review, a third reviewer 
(CS) determined whether the manuscript was eligible. 
 
We initially set out to include all systematic reviews of RCTs and individual RCTs on native 
vitamin D therapy in children with CKD 2-5D. However, the core leadership group 
acknowledged there are few RCTs or prospective observational studies of native vitamin D 
treatment in children with CKD 2-5D. We have therefore elected to perform a wider review of the 
literature and include studies with primary skeletal endpoints (including biochemical endpoints) 
in the following cohorts:   
- All systematic reviews of RCTs in healthy children, children with nutritional rickets and adults  
-  All systematic reviews of RCTs, individual RCTs and prospective observational studies in 
children with CKD 2-5D 
-  All RCTs in adults with CKD 2-5D  
- All RCTs in healthy children or children with nutritional rickets  
 
In addition, the recent Cochrane Review on interventions for metabolic bone disease in children 
with CKD13 and the evidence tables from the KDIGO CKD-MBD update document14 were used 
to evaluate all available studies.  
 
Data were extracted by at least 2 members of the core group, prepared in evidence tables (see 
all tables and supplement section) and GRADE-ed by all members of the core group. Only 
studies in the English language were included. Studies where skeletal endpoints were not 
applicable to the paediatric population (e.g. falls or hip fracture) were excluded. Comparison 
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between vitamin D2 and D3 was performed based on their effects on serum 25(OH)D 
levels. Some studies that were outside the remit of the literature review but contributed 
important information have been included in the discussion but did not influence the GRADE-ing 
of recommendations. Risk of bias assessment was only performed for RCTs in children due to 
resource constraints (see Supplemental Tables). 
 
GRADE system 
We have followed the Grading of Recommendation, Assessment, Development, and Evaluation 
(GRADE) method to develop the recommendations (Supplemental Tables 2A and 2B). Key 
aspects of this method include identification of the most important clinical questions for which 
treatment recommendations are needed, specification of the important outcomes, and use of a 
tested approach for deriving recommendations from the evidence15. This approach assigns 
separate grades for the quality of the evidence and for the strength of the recommendation22. 
The quality of evidence is graded as either high (A), moderate (B), low (C), or very low (D), and 
the strength of a recommendation as either level 1 (strong) or level 2 (weak or discretionary). 
 
AGREE-2 system 
We have developed our guideline based on the Appraisal of Guidelines for Research & 
Evaluation (AGREE)23 standards, an instrument that assesses the methodological rigour 
and transparency in which a guideline is developed.  
 
 
Clinical Practice Recommendations 
 
1. Assessing vitamin D status  
Recommendation: We recommend measuring serum 25(OH)D concentration for 
assessing the vitamin D status of children with CKD 2-5D.  
 
GRADE: This statement is based on in vitro data and therefore not graded. 
 
Evidence and rationale: Serum concentrations of 25(OH)D are the best marker of the vitamin 
D status of an individual because24-28: 
1. all pre-vitamin D metabolites from cutaneous synthesis or diet are rapidly converted into 
25(OH)D with no negative feedback to limit this conversion   
2. there is no significant storage in the liver 
3. the half-life in vivo is approximately 2 - 3 weeks 
4. in serum (and plasma) 25(OH)D is stable and resistant to repeated freeze-thaw cycles.  
 
The serum 1,25(OH)2D concentration is not a good measure of vitamin D status because25;27: 
1. conversion to 1,25(OH)2D depends on the availability of its substrate 25(OH)D 
2. conversion of 25(OH)D to 1,25(OH)2D is tightly regulated by circulating PTH, fibroblast 
growth factor 23 (FGF23), calcium, and phosphate 
3. the half-life in vivo is approximately 4 hours 
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Laboratory measurement of circulating 25(OH)D is challenging  due to its hydrophobic nature.  
Also, a stereoisomer 3-epi-25(OH)D3, that differs from 25(OH)D3 in the orientation of a hydroxyl 
group at C3, and is of unknown physiological function, may confound 25(OH)D 
measurements29.  
 
There are three techniques for measuring 25(OH)D concentrations in serum or plasma30-32:  
i) competitive protein binding assays utilizing vitamin D binding protein (VDBP) as the 
primary binding agent for 25(OH)D 
ii) competitive immunoassays utilizing 25(OH)D-specific antibodies as the primary binding 
agent. Techniques include radioimmunoassay, immuno-chemiluminescence and 
enzyme immunoassays. Irrespective of the mode used for detection, these assays 
differ with respect to the ability to discriminate between 25(OH)D metabolites -  
25(OH)D2, 25(OH)D3 and 3-epi-25(OH)D3.  
iii) high performance liquid chromatography (HPLC) coupled with either ultraviolet, 
colourimetric electrochemical detectors or tandem mass spectrometry (MS/MS). The 
latter is termed LC-MS/MS and combines the resolving power of HPLC with the 
specificity of mass spectrometry33. Although most chromatographic methods are 
developed and optimized in-house, commercial kits are available too.  
 
25(OH)D assays differ markedly with significant inter-assay and inter-laboratory variability30-32;34-
387KHUHLVOLWWOHFRQVHQVXVRQZKLFKDVVD\PHWKRGVKRXOGEHXVHGERWKLQWHUPVRIWKHDVVD\¶V
SUHFLVLRQ LH DELOLW\ WR PHDVXUH µWUXH¶ 2+' concentration) and repeatability within and 
between laboratories39.  It is encouraged that laboratories performing vitamin D analysis 
participate in the Vitamin D External Quality Assessment Scheme (DEQAS; 
http://www.deqas.org/) to ensure high analytical standards36-39. The choice of measurement 
technique depends on clinical requirements, i.e. when ergocalciferol is used for 
supplementation, the assay selected must be able to detect 25(OH)D2 and 25(OH)D3. 
Immunoassays that run on automated platforms allow high sample throughput at moderate 
costs and analytical precision is usually higher compared to manual assays38. HPLC or LC-
MS/MS assays require expensive equipment and skilled staff, but can differentiate between 
25(OH)D2, 25(OH)D3 and 3-epi-25(OH)D3. Clinicians must be aware of the limitations of current 
assays and refer to assay and laboratory-specific cut-off values. 
 
µ)UHH¶RUQRQ-protein bound 25(OH)D is biologically active and may be particularly important in 
patients with proteinuria, and may explain genetic variations in total 25(OH)D levels. However, 
there are no commercially available assays that have been well validated40.  Also, serum 
25(OH)D concentrations may be affected by rare genetic defects in the enzymes that regulate 
the metabolism and degradation of 25(OH)D and 1,25(OH)2D causing an increased risk of 
hypercalcaemia; these rare conditions are not discussed in this guideline document.  
  
 
2. Monitoring vitamin D concentration in serum 
Recommendation: We suggest the following schedule for measuring serum 25(OH)D 
concentration in children with CKD stage 2-5D: 
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- 6 ± 12 monthly depending on CKD stage in children not on vitamin D treatment   
- if normal levels, measure 6 -12 monthly (based on previous 25OHD level and stage of 
CKD)  
- if vit D supplementation required ± check levels after 3-months. If: 
x   normal levels, continue vit D supplements as above and measure levels 6-monthly 
x   ORZOHYHOVFRQVLGHURQHUHSHDWFRXUVHRIµLQWHQVLYHUHSODFHPHQWWUHDWPHQW¶DVGHVFULEHG
below and repeat levels in 3-months 
 
GRADE 
Strength of recommendation: 2 
Level of evidence: D 
  
Evidence and rationale: There are no studies that examine the frequency of 25(OH)D 
monitoring and outcomes. Based on the long half-life and perceived safety of native vitamin D 
therapy, we make the above suggestions. Reports suggest that frequent vitamin D 
measurements are costly, confusing and without credibility41. 
In addition to measuring serum 25(OH)D levels, measurement of serum calcium and urinary 
calcium excretion can be very helpful in detecting a risk of vitamin D toxicity from 
hypercalcaemia, hypercalciuria and nephrocalcinosis. This is particularly important during the 
high-GRVH µLQWHQVLYH UHSODFHPHQW SKDVH¶ RI WUHDWPHQW DQG LQ SDWLHQWV ZLWK impaired renal 
function such as neonates. This is discussed further under recommendation 6. 
 
 
3. Defining target levels of vitamin D 
Recommendation: We suggest that serum 25(OH)D concentrations are maintained above 
75nMol/L (>30ng/ml) in children with CKD stages 2 ± 5D.  
 
We classify vitamin D status as follows: 
sufficiency  > 75 nMol/L  (>30 ng/ml)  
insufficiency  50 ± 75 nMol/L  (20 ± 30 ng/ml)  
deficiency  12 ± 50 nMol/L  (5 - 20 ng/ml) 
severe deficiency <12 nMol/L (<5 ng/ml) 
 
GRADE 
Strength of recommendation: 2 
Level of evidence: C 
 
Evidence and rationale: There is no clear consensus on the definition of optimal vitamin D 
concentrations even in healthy children, and international guidelines differ in their 
recommendations of target 25(OH)D concentrations (Table 1). The Endocrine Society Clinical 
guideline42 recommend maintaining 25(OH)D >75nMol/L based on the effects on prevention of 
nutritional rickets, PTH suppression24 and optimal gut calcium absorption26;43. The Institute of 
Medicine (IOM)44 suggests that there is no improvement in outcome by increasing 25(OH)D 
concentration >50nMol/L, largely based on the histological presence of bone disease in post-
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mortem specimens from healthy individuals45. Similarly, in a study of 52 post-mortem 
examinations in children between 2 days and 10 years of age, 33% had growth plate 
abnormalities that were associated with 25(OH)D concentrations between 25 ± 50nMol/L46; 
however, underlying illnesses contributing to death may have affected the growth plate. 
Importantly, gut calcium absorption or increased PTH levels, that are known to precede the 
development of overt rickets (Table 2)24, have not been considered when defining normal 
25(OH)D concentrations. In otherwise healthy children an increased incidence of nutritional 
rickets is reported with 25(OH)D levels <30nMol/L47-50, particularly if there is concomitant 
calcium deficiency51. Seasonal variations in 25(OH)D levels are reported52, emphasizing the 
importance of maintaining higher concentrations so as to prevent seasonal fluctuations or 
prolonged periods of low 25(OH)D that increase the risk of developing rickets. A systematic 
review of RCTs of native vitamin D supplementation versus placebo in otherwise healthy 
children who were vitamin D deficient, clinically useful improvements in lumbar spine bone 
mineral density and total body bone mineral content were noted, but only on sub-group analysis 
in those with 25(OH)D levels below 35 nMol/L, and must be interpreted with caution(Table 
3A)53. Also, the vitamin D receptor genotype may influence this response as shown in an RCT 
of healthy girls (Table 3B)54. 
 
There are few studies in children or adults with CKD that examine the effects of 25(OH)D 
concentrations on bone, and the optimal target level of 25(OH)D is unclear and may need to be 
higher than that in the general population. In the only RCT of native vitamin D therapy in 
children with CKD it was shown that children on ergocalciferol who achieved 25(OH)D levels 
>75nMol/L had a significantly longer time to development of secondary hyperparathyroidism 
(hazard ratio=0.30, 95% confidence interval=0.09±0.93; Table 4A) compared to those on 
placebo8.In a prospective longitudinal study of 170 children and adolescents with CKD stages 2-
5D lower serum 25(OH)D and calcium levels were independently associated with lower tibial 
cortical volumetric BMD Z-scores55, but no correlation was found between 25(OH)D levels and 
fracture risk56. A meta-analysis of nutritional vitamin D compounds in adult CKD and dialysis 
patients showed that PTH levels decreased significantly with cholecalciferol treatment57. 
Although no association has been found between 25(OH)D dose or level on PTH suppression, 
significantly higher doses of daily or weekly cholecalciferol treatment were used in all the RCTs 
in this meta-analysis. In a cross-sectional analysis of >14,000 adults with CKD stages 1-5, there 
was a significant inverse association of PTH and serum 25(OH)D, but no further decrease in 
PTH was seen with 25(OH)D above 105 ± 120nMol/L in all CKD stages58, implying that CKD 
patients may require significantly higher 25(OH)D levels to achieve target PTH values compared 
to the healthy population. K/DOQI recommend maintaining 25(OH)D concentrations above 
75nMol/L11;12 as concentrations below this are associated with hyperparathyroidism, lower 
BMD59 and hip fractures in adults60. Higher 25(OH)D concentrations were not associated with 
increased rates of hypercalcaemia or hyperphosphataemia in either of the above studies. A safe 
upper limit for 25(OH)D is discussed under recommendation 7 below. A recent report of nearly 
700 children with CKD across Europe has shown that disease-related factors and vitamin D 
supplementation are the main correlates of vitamin D status in children with CKD, whereas 
variations in the vitamin D binding protein showed only a weak association with the vitamin D 
status61. 
10 
 
 
 
4. Which patients with CKD need vitamin D supplements? 
Recommendation: We suggest using native vitamin D supplements for the treatment of 
vitamin D deficiency in children with CKD stages 2-5D who have serum 25(OH)D 
concentrations below 75nMol/L. In children with CKD stages 2-3 native vitamin D 
supplements may be used for the prevention or treatment of secondary 
hyperparathyroidism. 
 
GRADE 
Strength of recommendation: 2 
Level of evidence: B 
 
Evidence and rationale: CKD patients are at greater risk of vitamin D deficiency because they 
are less active and have less sunlight exposure, uraemia reduces the endogenous synthesis of 
vitamin D in the skin62, ingestion of foods that are natural sources of vitamin D may be 
diminished63, there is reduced hepatic production of 25(OH)D from substrate and loss of vitamin 
D binding protein in the urine64;65 or peritoneal dialysate66.  
 
In an RCT conducted in 40 children with CKD stages 2 ± 4, ergocalciferol supplementation 
significantly delayed the time to development of secondary hyperparathyroidism compared with 
placebo (Table 4A and Supplemental Table 3)8. Only one patient had CKD 4, making the 
recommendations only applicable to patients in CKD 2-3. Several uncontrolled trials of vitamin 
D2 or D3 using different treatment schedules have been conducted in children and show 
different responses to PTH suppression, but all confirm safety in terms of no risk of 
hypercalcaemia or hyperphosphataemia (Table 4B)67-70. In adults with CKD not on dialysis 
ergocalciferol reduced PTH levels by 20 to 25% in those with CKD 3, but it was ineffective in 
patients with stage 4 CKD71;72. In a systematic review73 and meta-analysis57 of observational 
studies and RCTs (Table 5A) ergocalciferol or cholecalciferol supplementation improved 
biochemical end-points including a reduction in PTH levels in adult CKD and dialysis 
patients57;73. Most reports suggest that in dialysis patients, and possibly in CKD 4-5, 25(OH)D 
supplementation alone may not be able to increase 1,25(OH)2D levels (Table 5B)74-79. However, 
a recent RCT in adults on haemodialysis has shown that high dose weekly ergocalciferol 
supplementation (50,000 IU orally weekly) increased their serum 25(OH)D levels to a normal 
range (defined as >80nMol/L in this study) with no risk of hypercalcaemia or 
hyperphosphataemia, but 50% of patients still required active vitamin D supplementation for 
hyperparathyroidism80.  
 
In all children, particularly during periods of active growth, the body is in a positive calcium 
balance and it is important to keep serum calcium levels in the normal range. In children with 
CKD and on dialysis low serum calcium levels are associated with impaired bone mineralisation 
on histology1;81 and reduced tibial cortical bone mineral density on peripheral quantitative CT 
scan55, that in turn is associated with an increased fracture risk56. The guideline committee 
holds the opinion that native vitamin D therapy is used in children with CKD stages 2-5 and on 
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dialysis, and active vitamin D therapy added in patients who have hyperparathyroidism despite 
normal 25(OH)D levels, provided they do not have hypercalcaemia and/or hyperphosphataemia. 
 
 
5. Type of vitamin D supplement? 
Recommendation: We suggest using either vitamin D2 (ergocalciferol) or vitamin D3 
(cholecalciferol)
 
treatment in children with CKD 2 ± 5D to increase serum 25(OH)D levels 
to the target range. 
 
GRADE 
Strength of recommendation: 2 
Level of evidence: D 
 
Evidence and rationale: Three randomized trials in healthy children and those with nutritional 
rickets have examined the effects of vitamin D2 and vitamin D3 supplementation (Tables 6A and 
Supplemental Table 4)82-84. The patient cohorts, dosage of vitamin D, frequency of 
administration and duration of treatment varied widely, and no difference in 25(OH)D levels was 
seen between D2 and D3 supplementation82-84. One systematic review in healthy adults has 
compared the effects of vitamin D2 and vitamin D3 supplementation (Table 6B)85. Although there 
was considerable heterogeneity in the dosage, route and frequency of administration as well as 
the type of vitamin D assay used, there was no meaningful difference between vitamin D2 and 
vitamin D3 supplementation with daily oral treatment85. There is only one RCT in adults on 
haemodialysis that has compared the effects of high dose monthly supplementation with vitamin 
D2 versus D3 which suggested that higher 25(OH)D levels are obtained with monthly D3 
compared with D2 supplementation (Table 6C)53;86. The European Society of Paediatric 
Endocrinology42, the US Endocrine Society87 and the Scientific Advisory Committee on 
Nutrition88 suggest using daily oral vitamin D2 or vitamin D3 for the prevention or treatment of 
nutritional rickets.  
 
The currently available guidelines on CKD-MBD management vary in their recommendations 
(Table 7): .'24,¶VUHFRPPHQGDWLRQonly mentions vitamin D2 11;12, KDIGO 2009 makes 
no recommendations for use of cholecalciferol over ergocalciferol3 whereas European Renal 
Best Practice Group 2010 recommended cholecalciferol or other 25(OH)D analogues89. An RCT 
in children with CKD 2-4 indicated that ergocalciferol supplementation effectively increases 
serum 25(OH)D levels to the normal range (Table 4A)8. Other uncontrolled trials in children 
have used both ergocalciferol and cholecalciferol, but in varying treatment schedules and with 
variable 25(OH)D concentrations achieved (Table 4B)67-70. A vitamin D derivative, calcifediol 
(25-hydroxyvitamin D3, that requires only 1D-hydroxylation for activation), has been approved 
as a modified release preparation by the FDA based upon 2 RCTs in adults CKD patients, as 
the gradual delivery of calcifediol is thought to improve PTH control90. There are no published 
trials in children so far. 
 
An important cautionary point needs to be kept in mind. Pharmaceutical grade products are 
available for Vitamin D3, but the availability of vitamin D2 products with pharmaceutical quality in 
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doses suitable for children is limited. Pharmaceutical grade products provide assurance that the 
dose given is the dose prescribed whereas in non-pharmaceutical over-the-counter products 
there can be a huge discrepancy between the indicated and actual vitamin D dose present in 
the supplement 91 
 
 
6. Dosage and frequency of treatment with native vitamin D supplements 
Recommendation: We suggest using a treatment regimen, guided by age and vitamin D 
concentration, for the prevention and treatment of vitamin D deficiency in children with 
CKD 2-5D. Mega-dose vitamin D therapy is not recommended. 
 
GRADE 
Strength of recommendation:  2 
Level of evidence: C  
 
Evidence and rationale: There is no clear consensus between guideline committees on the 
type of native vitamin D supplement, its dosage, frequency of administration or duration of 
treatment12;42;92;93 in healthy children (Table 1) or children with CKD (Table 7). All guidelines 
recommend a loading regimen or intensive replacement period for a variable duration of 4 ± 12 
weeks followed by a maintenance regimen. Unlike the dosage recommendations for vitamin D 
treatment in healthy children that are based on age42;92;93, the K/DOQI recommends escalating 
doses for intensive replacement depending on the baseline 25(OH)D level12.  
 
There is only one RCT of native vitamin D treatment in children with CKD (Table 4A)8 that has 
been considered a high quality RCT with appropriate double blinding, and a low risk of bias, in 
the Cochrane analysis on metabolic bone disease in children with CKD13. This RCT has used a 
modified version of the K/DOQI vitamin D treatment recommendation (Table 8), adjusting doses 
fRUERWKEDVHOLQH2+'OHYHOVDQGDOVRWKHFKLOG¶VDJH,WVKRZHGWKDWHlevated PTH levels 
developed significantly later in ergocalciferol treated children, though the number with elevated 
PTH levels did not differ between groups at final follow-up at one year8. The ergocalciferol-
treated children had a statistically significant increase in 25(OH)D levels between baseline and 
3 months of intensive replacement treatment with 80% of children achieving 25(OH)D levels in 
the normal range after intensive replacement treatment, whereas only 60% children continued 
to have normal 25(OH)D levels after maintenance treatment. However, it was more difficult to 
achieve and maintain normal 25(OH)D levels in CKD stages 3±4 compared with stage 28, 
suggesting that higher doses of ergocalciferol may be required in children with CKD 3, or that a 
repeat course of intensive replacement treatment may be required in those who have not 
achieved normal 25(OH)D levels. Other non-randomised prospective studies in children with 
CKD67-70 (Table 4B) have used variable doses and treatment regimens, and implied the efficacy 
of ergocalciferol or cholecalciferol in reducing PTH levels68;70.  
 
None of the studies adjust vitamin D doses for body weight or body surface area, and this may 
account for the variations in 25(OH)D levels achieved94. However, the ergocalciferol RCT did 
not show any variation in 25(OH)D levels achieved based on the ergocalciferol dose by body 
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weight or body surface area, but given the small patient numbers, this cannot be excluded and 
warrants further study. Until further studies in children with CKD and on dialysis are available, 
the guideline committee suggest using a treatment schedule guided by age and vitamin D level 
for native vitamin D supplementation in children with CKD 2-5D (Table 8). As per the K/DOQI 
recommendations, we suggest different dosing schedules for children <1 year and above 1 year 
in age, although there are no studies to qualify this statement. Also, particularly when using 
higher doses during the intensive replacement phase, physicians may choose to use a smaller 
GRVHEDVHGRQWKHFKLOG¶VZHLJKW 
 
During the high-GRVH µLQWHQVLYHUHSODFHPHQWSKDVH¶RI WUHDWPHQWDQG LQSDWLHQWVZLWK LPSDLUHG
renal function such as neonates or children with CKD, we suggest measuring serum and urinary 
calcium to assess the risk of vitamin D toxicity from hypercalcaemia, hypercalciuria and 
nephrocalcinosis. In addition, clinicians are advised to take into account the vitamin D intake 
from formula feeds and fortified foods.  
 
,PSRUWDQWO\DOWKRXJKWKHµstoss UHJLPHQ¶ (i.e. 300,000 IU and 600,000 IU as single mega-dose 
vitamin D therapy) appears attractive and may overcome issues of compliance, it is not shown 
to affect the rate of improvement of rickets, but can cause hypercalcaemia even in healthy 
children95;96. RCTs in healthy adults have shown that high dose monthly treatment with 
ergocalciferol or cholecalciferol97;98, although achieving normal 25(OH)D levels, was associated 
with a higher risk of fractures, particularly in the first 3 months of treatment. It is speculated that 
high dose native vitamin D supplements may cause an acute increase in 1,25(OH)2D levels, 
that, in the presence of hypocalcaemia, may be catabolic to bone97;99. In adults with 
osteoporosis a single dose of 300,000IU cholecalciferol caused a 50% increase in FGF23 levels 
from baseline100. Given that hypercalcaemia can cause a significant acute decline in renal 
function particularly in CKD patients101, and that FGF23 is associated with adverse cardiac 
effects, we do not recommend mega-dose vitamin D treatment regimens, such as the stoss 
regimen, in children with CKD. More modest high-dose treatment with 80,000 and 100,000 IU 
cholecalciferol is available and used in some countries, but there is no evidence for this dosing 
regimen. Given the longer half-life of vitamin D3 compared to vitamin D2, if a weekly dosing 
schedule is followed, vitamin D3 is recommended compared to vitamin D2. Based on current 
knowledge, the guideline committee suggests that mega-dose monthly (or 3-monthly) treatment 
is avoided. There are no studies on vitamin D therapy in children with failed transplants who are 
in CKD or require dialysis but remain on immunosuppression, and we are not able to make a 
separate comment about them. 
 
 
7. Vitamin D toxicity  
Recommendation: We suggest that vitamin D supplementation is stopped at serum 
25(OH)D concentrations of 120nMol/L (48ng/ml). Symptomatic toxicity from Vitamin D is 
defined as serum 25(OH)D above 250nMol/L with hypercalcaemia, hypercalciuria and 
suppressed PTH.  
 
GRADE 
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Strength of recommendation: 2 
Level of evidence: D 
 
Evidence and rationale:  Intoxication from vitamin D is largely reported from the use of very 
high doses of ergocalciferol or cholecalciferol over prolonged periods of time, or from accidental 
or iatrogenic overdose102-105. High serum 25(OH)D levels can cause hypercalcaemia and 
associated sequelae including pancreatitis, hypercalciuria, and if prolonged, nephrocalcinosis 
and renal failure. RCTs in healthy children report symptomatic toxicity only at levels >500 
nMol/L102. Genetic variations in vitamin D metabolism may lead to elevated 25(OH)D levels at 
much lower doses of vitamin D treatment; these are beyond the scope of this guideline.  
 
Patients with CKD may have reduced urinary calcium excretion and be more prone to 
nephrocalcinosis and renal impairment106. A 15-year analysis of the Third National Health and 
Nutrition Examination Survey (NHANES III) database of >15,000 adults in the general 
population has suggested a reverse J-shaped association between serum 25(OH)D and all-
cause mortality, with an increased mortality at serum 25(OH)D levels above 120 nMol/L (RR = 
1.5, 95% CI = 1.02±2.3)107. Thus, we suggest a more prudent recommendation for stopping 
ergocalciferol or cholecalciferol supplements at serum 25(OH)D levels of 120nMol/L, and define 
symptomatic toxicity at serum 25(OH)D levels >250nMol/L with hypercalcaemia, hypercalciuria 
and suppressed PTH. 
 
 
Summary of Recommendations 
A summary of recommendations is provided in Supplemental Table 5. 
 
 
Audit Recommendations 
The ESPN CKD-MBD and Dialysis WGs will audit the effectiveness and safety of the 
recommendations within its WG. Serum calcium and 25(OH)D levels and urinary calcium 
excretion will be measured during the intensive replacement phase of therapy as an early and 
sensitive measure of hypercalciuria (recommendation 6).  The audit outcomes will be published 
and recommendations updated as necessary. 
 
 
Research Recommendations  
Research recommendations for native and active vitamin D treatment are provided in the 
GRFXPHQWRQµ$FWLYH9LWDPLQ'WKHUDS\UHFRPPHQGDWLRQV¶ (Ref xx). 
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